How I treat myeloproliferative neoplasms in pregnancy

2.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

3.

Alimam

S

,

Bewley

S

,

Chappell

LC

, et al.

Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study

.

Br J Haematol

.

2016

;

175

(

1

):

31

-

36

.

4.

Landtblom

AR

,

Andersson

TM

,

Johansson

ALV

, et al.

Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden

.

Leukemia

.

2022

;

36

(

10

):

2461

-

2467

.

5.

Williams

N

,

Lee

J

,

Mitchell

E

, et al.

Life histories of myeloproliferative neoplasms inferred from phylogenies

.

Nature

.

2022

;

602

(

7895

):

162

-

168

.

6.

How

J

,

Garcia

JS

,

Mullally

A

.

Biology and therapeutic targeting of molecular mechanisms in MPNs

.

Blood

.

2023

;

141

(

16

):

1922

-

1933

.

7.

Gangat

N

,

Tefferi

A

.

Myeloproliferative neoplasms and pregnancy: overview and practice recommendations

.

Am J Hematol

.

2021

;

96

(

3

):

354

-

366

.

8.

Tuffnell

D

,

Knight

M

,

Mackillop

L

;

on behalf of the MBRRACE-UK VTE chapter-writing group

. Lessons for prevention and treatment of thrombosis and thromboembolism. In:

Knight

M

,

Bunch

K

,

Tuffnell

D

, eds.

Saving Lives, Improving Mothers’ Care - Lessons Learned to Inform Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2014-16

.

National Perinatal Epidemiology Unit, University of Oxford

;

2018

:

34

-

41

.

9.

Robinson

SE

,

Harrison

CN

.

How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy

.

Br J Haematol

.

2020

;

189

(

4

):

625

-

634

.

10.

How

J

,

Leiva

O

,

Bogue

T

, et al.

Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia

.

Leuk Res

.

2020

;

98

:

106459

.

11.

Gangat

N

,

Joshi

M

,

Shah

S

, et al.

Pregnancy outcomes in myeloproliferative neoplasms: a Mayo Clinic report on 102 pregnancies

.

Am J Hematol

.

2020

;

95

(

5

):

E114

-

E117

.

12.

Sokołowska

BS

,

Jawniak

D

.

Pregnancy outcomes in patients with Philadelphia negative myeloproliferative neoplasms – palg (polish adult leukemia group) a recent, extended retrospective analysis [abstract]

.

EHA Library

.

2020

. Abstract EP1121.

13.

How

Chi-Joan

,

Leiva

O

,

Bogue

T

, et al.

Pregnancy outcomes, risk factors, and gestational cell count trends in pregnant women with essential thrombocythemia and polycythemia vera [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

4172

.

14.

Lapoirie

J

,

Contis

A

,

Guy

A

, et al.

Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms

.

J Matern Fetal Neonatal Med

.

2020

;

33

(

1

):

49

-

56

.

15.

Bertozzi

I

,

Rumi

E

,

Cavalloni

C

,

Cazzola

M

,

Fabris

F

,

Randi

ML

.

Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera

.

Am J Hematol

.

2018

;

93

(

9

):

E234

-

E235

.

16.

Griesshammer

M

,

Schauer

S

. Outcomes of 121 pregnancies in patients with polycythemia vera (PV).

EHA Library

;

2016

:

S110

.

17.

Palandri

F

,

Polverelli

N

,

Ottaviani

E

,

Castagnetti

F

,

Baccarani

M

,

Vianelli

N

.

Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients

.

Haematologica

.

2010

;

95

(

6

):

1038

-

1040

.

18.

Melillo

L

,

Tieghi

A

,

Candoni

A

, et al.

Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry

.

Am J Hematol

.

2009

;

84

(

10

):

636

-

640

.

19.

Gangat

N

,

Wolanskyj

AP

,

Schwager

S

,

Tefferi

A

.

Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies

.

Eur J Haematol

.

2009

;

82

(

5

):

350

-

353

.

20.

Tulpule

S

,

Bewley

S

,

Robinson

SE

,

Radia

D

,

Nelson-Piercy

C

,

Harrison

CN

.

The management and outcome of four pregnancies in women with idiopathic myelofibrosis

.

Br J Haematol

.

2008

;

142

(

3

):

480

-

482

.

21.

Passamonti

F

,

Randi

ML

,

Rumi

E

, et al.

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

.

Blood

.

2007

;

110

(

2

):

485

-

489

.

22.

Robinson

S

,

Bewley

S

,

Hunt

BJ

,

Radia

DH

,

Harrison

CN

.

The management and outcome of 18 pregnancies in women with polycythemia vera

.

Haematologica

.

2005

;

90

(

11

):

1477

-

1483

.

23.

Niittyvuopio

R

,

Juvonen

E

,

Kaaja

R

, et al.

Pregnancy in essential thrombocythaemia: experience with 40 pregnancies

.

Eur J Haematol

.

2004

;

73

(

6

):

431

-

436

.

24.

Wright

CA

,

Tefferi

A

.

A single institutional experience with 43 pregnancies in essential thrombocythemia

.

Eur J Haematol

.

2001

;

66

(

3

):

152

-

159

.

25.

Cincotta

R

,

Higgins

JR

,

Tippett

C

, et al.

Management of essential thrombocythaemia during pregnancy

.

Aust N Z J Obstet Gynaecol

.

2000

;

40

(

1

):

33

-

37

.

26.

Bangerter

M

,

Güthner

C

,

Beneke

H

,

Hildebrand

A

,

Grünewald

M

,

Griesshammer

M

.

Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies

.

Eur J Haematol

.

2000

;

65

(

3

):

165

-

169

.

27.

Randi

ML

,

Rossi

C

,

Fabris

F

,

Girolami

A

.

Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies

.

J Intern Med

.

1999

;

246

(

5

):

517

-

518

.

28.

Pagliaro

P

,

Arrigoni

L

,

Muggiasca

ML

,

Poggio

M

,

Russo

U

,

Rossi

E

.

Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases

.

Am J Hematol

.

1996

;

53

(

1

):

6

-

10

.

29.

Beressi

AH

,

Tefferi

A

,

Silverstein

MN

,

Petitt

RM

,

Hoagland

HC

.

Outcome analysis of 34 pregnancies in women with essential thrombocythemia

.

Arch Intern Med

.

1995

;

155

(

11

):

1217

-

1222

.

30.

NHS England. Saving babies’ lives version three: a care bundle for reducing perinatal mortality; 2023. Updated 29 September 2023

. Accessed 1 September 2023. https://www.england.nhs.uk/publication/saving-babies-lives-version-three/.

31.

Royal College of Obstetricians & Gynaecologists

.

Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium (Green-top Guideline No. 37a)

. Accessed 1 September 2023. https://www.rcog.org.uk/media/qejfhcaj/gtg-37a.pdf.

32.

Vandekerckhove

M

,

Guignard

M

,

Civadier

MS

,

Benachi

A

,

Bouyer

J

.

Impact of maternal age on obstetric and neonatal morbidity: a retrospective cohort study

.

BMC Pregnancy Childbirth

.

2021

;

21

(

1

):

732

.

33.

Godfrey

AL

,

Green

AC

,

Harrison

CN

.

Essential thrombocythemia: challenges in clinical practice and future prospects

.

Blood

.

2023

;

141

(

16

):

1943

-

1953

.

34.

Rolnik

DL

,

Wright

D

,

Poon

LC

, et al.

Aspirin versus placebo in pregnancies at high risk of preterm pre-eclampsia

.

N Engl J Med

.

2017

;

377

(

7

):

613

-

622

.

35.

Ayala

DE

,

Ucieda

R

,

Hermida

RC

.

Chronology with low-dose aspirin for prevention of complications in pregnancy

.

Chronobiol Int

.

2013

;

30

(

1-2

):

260

-

279

.

36.

Ghesquiere

L

,

Guerby

P

,

Marchant

I

, et al.

Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis

.

Am J Obstet Gynecol MFM

.

2023

;

5

(

7

):

101000

.

37.

NG133 hypertension in pregnancy: diagnosis and management: visual summary on planning care for women at moderate and high risk of pre-eclampsia

. Accessed 17 April 2023. https://www.nice.org.uk/.

38.

Kiladjian

JJ

,

Barbui

T

.

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

.

Leukemia

.

2020

;

34

(

11

):

2837

-

2839

.

39.

Barbui

T

,

Vannucchi

AM

,

De Stefano

V

, et al.

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

.

Lancet Haematol

.

2021

;

8

(

3

):

e175

-

e184

.

40.

McMullin

MFF

,

Mead

AJ

,

Ali

S

, et al;

British Society for Haematology Guideline

.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology guideline

.

Br J Haematol

.

2019

;

184

(

2

):

161

-

175

.

41.

Bates

SM

,

Rajasekhar

A

,

Middeldorp

S

, et al.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy

.

Blood Adv

.

2018

;

2

(

22

):

3317

-

3359

.

42.

Miyakis

S

,

Lockshin

MD

,

Atsumi

T

, et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

.

J Thromb Haemost

.

2006

;

4

(

2

):

295

-

306

.

43.

Maze

D

,

Kazi

S

,

Gupta

V

, et al.

Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis

.

JAMA Netw Open

.

2019 2

;

2

(

10

):

e1912666

.

44.

Beauverd

Y

,

Radia

D

,

Cargo

C

, et al.

Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series

.

Haematologica

.

2016

;

101

(

5

):

e182

-

e184

.

45.

Wille

K

,

Brouka

M

,

Bernhardt

J

, et al.

Outcome of 129 pregnancies in polycythemia vera patients: a report of the European LeukemiaNET

.

Hemasphere

.

2023

;

7

(

5

):

e882

.

46.

Okikiolu

J

,

Woodley

C

,

Cadman-Davies

L

, et al.

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

.

Leuk Res Rep

.

2023

;

19

:

100360

.

47.

Harrison

CN

,

Nangalia

J

,

Boucher

R

, et al.

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

.

J Clin Oncol

.

2023

;

41

(

19

):

3534

-

3544

.

48.

Mithridate: a phase III, randomised, open-label, multicenter international trial comparing ruxolitinib with either hydroxycarbamide or interferon alpha as first-line therapy for high-risk polycythemia vera (PV) ClinicalTrials.gov Identifier: NCT04116502

. Updated 9 December 2022. Accessed 1 September 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04116502?term=NCT04116502&draw=2&rank=1.

49.

Kiladjian

JJ

,

Cassinat

B

.

Myeloproliferative neoplasms and splanchnic vein thrombosis: contemporary diagnostic and therapeutic strategies

.

Am J Hematol

.

2023

;

98

(

5

):

794

-

800

.